Literature DB >> 22809835

Hylan G-F 20 maintains cartilage integrity and decreases osteophyte formation in osteoarthritis through both anabolic and anti-catabolic mechanisms.

P Li1, D Raitcheva, M Hawes, N Moran, X Yu, F Wang, G L Matthews.   

Abstract

OBJECTIVE: To perform a molecular mechanism-based investigation of the chondroprotective potential of hylan G-F 20.
METHOD: The effects of hylan G-F 20 on IL-1β-induced glycosaminoglycan (GAG) depletion and matrix metalloproteinase (MMP) expression in bovine and human cartilage explants were evaluated. Three weekly intra-articular hylan G-F 20 or control injections were administered 4 weeks post-operatively to rabbits with surgically induced osteoarthritis (OA). Cartilage histopathologic scores and osteophyte size were evaluated at 1, 4, and 8 weeks post-injections. Histomorphometry and immunostaining were used to quantify cartilage area and type II collagen (Col II) intensity, and real-time polymerase chain reaction (PCR) was used to examine the mRNA levels of Col2A1, MMP-13, -16 and IL-1β at 1 week.
RESULTS: Hylan G-F 20 retained GAG in IL-1β-exposed bovine and human cartilage explants and abrogated IL-1β-mediated increases in MMP-1, -3, and -13 in human explant culture. Hylan G-F 20‒treated OA joints had significantly better cartilage integrity at 1 and 4 weeks post-treatment and significantly smaller osteophytes at 4 weeks compared with control. Col2A1 mRNA increased with hylan G-F 20 treatment, which correlated with a trend toward increased Col II immunostaining. MMP-13 and -16 mRNAs increased in OA cartilage, but were not significantly altered by hylan G-F 20. IL-1β mRNA was undetectable in cartilage and unaltered in the synovium.
CONCLUSIONS: Hylan G-F 20 improved cartilage integrity and decreased osteophyte formation in the rabbit model of OA. Our results suggest that hylan G-F 20 may stimulate cartilage repair by increasing Col II, and inhibit IL-1β-mediated matrix degradation by decreasing MMPs.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22809835     DOI: 10.1016/j.joca.2012.07.004

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  22 in total

Review 1.  Strategies for controlled delivery of biologics for cartilage repair.

Authors:  Johnny Lam; Steven Lu; F Kurtis Kasper; Antonios G Mikos
Journal:  Adv Drug Deliv Rev       Date:  2014-06-30       Impact factor: 15.470

Review 2.  [Injection treatment with hyaluronic acid].

Authors:  J Jerosch
Journal:  Z Rheumatol       Date:  2015-11       Impact factor: 1.372

Review 3.  Intra-articular hyaluronic acid in the treatment of knee osteoarthritis: a Canadian evidence-based perspective.

Authors:  Mohit Bhandari; Raveendhara R Bannuru; Eric M Babins; Johanne Martel-Pelletier; Moin Khan; Jean-Pierre Raynauld; Renata Frankovich; Deanna Mcleod; Tahira Devji; Mark Phillips; Emil H Schemitsch; Jean-Pierre Pelletier
Journal:  Ther Adv Musculoskelet Dis       Date:  2017-09-12       Impact factor: 5.346

4.  Decision Algorithms for the Retreatment with Viscosupplementation in Patients Suffering from Knee Osteoarthritis: Recommendations from the EUROpean VIScosupplementation COnsensus Group (EUROVISCO).

Authors:  Raghu Raman; Yves Henrotin; Xavier Chevalier; Alberto Migliore; Jörg Jerosch; Jordi Montfort; Hervé Bard; Dominique Baron; Pascal Richette; Thierry Conrozier
Journal:  Cartilage       Date:  2017-02-01       Impact factor: 4.634

5.  Overexpression of cystatin C in synovium does not reduce synovitis or cartilage degradation in established osteoarthritis.

Authors:  Sirkka Kyostio-Moore; Susan Piraino; Patricia Berthelette; Nance Moran; Joseph Serriello; Alison Bendele; Cathleen Sookdeo; Bindu Nambiar; Patty Ewing; Donna Armentano; Gloria L Matthews
Journal:  Arthritis Res Ther       Date:  2015-01-16       Impact factor: 5.156

6.  Injectable hyaluronic-acid-doxycycline hydrogel therapy in experimental rabbit osteoarthritis.

Authors:  Hsien-Tsung Lu; Ming-Thau Sheu; Yung-Feng Lin; Jai Lan; Yi-Ping Chin; Ming-Shium Hsieh; Chao-Wen Cheng; Chien-Ho Chen
Journal:  BMC Vet Res       Date:  2013-04-10       Impact factor: 2.741

7.  Pain relief and improved physical function in knee osteoarthritis patients receiving ongoing hylan G-F 20, a high-molecular-weight hyaluronan, versus other treatment options: data from a large real-world longitudinal cohort in Canada.

Authors:  Robert J Petrella; Craig Wakeford
Journal:  Drug Des Devel Ther       Date:  2015-10-15       Impact factor: 4.162

8.  Pulsed electromagnetic field therapy for management of osteoarthritis-related pain, stiffness and physical function: clinical experience in the elderly.

Authors:  Tommaso Iannitti; Gregorio Fistetto; Anna Esposito; Valentina Rottigni; Beniamino Palmieri
Journal:  Clin Interv Aging       Date:  2013-09-26       Impact factor: 4.458

9.  Weekly injections of Hylan G-F 20 delay cartilage degeneration in partial meniscectomized rat knees.

Authors:  Katsuaki Yanagisawa; Takeshi Muneta; Nobutake Ozeki; Yusuke Nakagawa; Mio Udo; Ryusuke Saito; Hideyuki Koga; Kunikazu Tsuji; Ichiro Sekiya
Journal:  BMC Musculoskelet Disord       Date:  2016-04-27       Impact factor: 2.362

10.  Characterization of viscosupplementation formulations using chemical exchange saturation transfer (ViscoCEST).

Authors:  Mohammad Haris; Anup Singh; Sanjana Reddy; Puneet Bagga; J Bruce Kneeland; Fotios P Tjoumakaris; Hari Hariharan; Francesco M Marincola; Ravinder Reddy
Journal:  J Transl Med       Date:  2016-04-12       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.